Research Analysts Set Expectations for CLDX FY2028 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Partnrs decreased their FY2028 earnings estimates for shares of Celldex Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of $0.99 for the year, down from their previous forecast of $1.04. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2029 earnings at $6.67 EPS.

A number of other research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Trading Down 3.5 %

Celldex Therapeutics stock opened at $22.47 on Thursday. The business’s 50 day simple moving average is $25.23 and its 200 day simple moving average is $30.62. Celldex Therapeutics has a 12 month low of $22.08 and a 12 month high of $53.18. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -8.74 and a beta of 1.60.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AlphaQuest LLC grew its position in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,705 shares in the last quarter. E Fund Management Co. Ltd. bought a new stake in Celldex Therapeutics during the fourth quarter valued at $273,000. Charles Schwab Investment Management Inc. grew its position in Celldex Therapeutics by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock worth $13,755,000 after buying an additional 5,474 shares in the last quarter. Fisher Asset Management LLC increased its stake in Celldex Therapeutics by 20.9% in the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company’s stock worth $11,435,000 after acquiring an additional 78,145 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in shares of Celldex Therapeutics by 128.9% in the 4th quarter. Los Angeles Capital Management LLC now owns 15,421 shares of the biopharmaceutical company’s stock valued at $390,000 after acquiring an additional 8,683 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.80% of the stock is currently owned by insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.